The stock of Travere Therapeutics Inc (TVTX) has seen a -3.91% decrease in the past week, with a 47.73% gain in the past month, and a 72.93% flourish in the past quarter. The volatility ratio for the week is 5.88%, and the volatility levels for the past 30 days are at 7.27% for TVTX. The simple moving average for the last 20 days is 5.78% for TVTX’s stock, with a simple moving average of 63.41% for the last 200 days.
Is It Worth Investing in Travere Therapeutics Inc (NASDAQ: TVTX) Right Now?
The stock has a 36-month beta value of 0.73. Opinions on the stock are mixed, with 6 analysts rating it as a “buy,” 5 as “overweight,” 5 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for TVTX is 75.34M, and at present, short sellers hold a 11.49% of that float. On October 02, 2024, the average trading volume of TVTX was 1.45M shares.
TVTX) stock’s latest price update
Travere Therapeutics Inc (NASDAQ: TVTX) has experienced a decline in its stock price by 0.00 compared to its previous closing price of 13.99. However, the company has seen a fall of -3.91% in its stock price over the last five trading days. accesswire.com reported 2024-10-01 that NEW YORK, NY / ACCESSWIRE / October 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Travere Therapeutics, Inc. (“Travere Therapeutics, Inc.”) (NASDAQ:TVTX) concerning possible violations of federal securities laws. Travere issued a press release on September 26, 2024, “announc[ing] a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for the treatment of classical homocystinuria (HCU).
Analysts’ Opinion of TVTX
Many brokerage firms have already submitted their reports for TVTX stocks, with Guggenheim repeating the rating for TVTX by listing it as a “Buy.” The predicted price for TVTX in the upcoming period, according to Guggenheim is $25 based on the research report published on September 09, 2024 of the current year 2024.
Citigroup gave a rating of “Buy” to TVTX, setting the target price at $10 in the report published on December 05th of the previous year.
TVTX Trading at 30.18% from the 50-Day Moving Average
After a stumble in the market that brought TVTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -8.92% of loss for the given period.
Volatility was left at 7.27%, however, over the last 30 days, the volatility rate increased by 5.88%, as shares surge +45.73% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +44.97% upper at present.
During the last 5 trading sessions, TVTX fell by -3.91%, which changed the moving average for the period of 200-days by +57.19% in comparison to the 20-day moving average, which settled at $13.45. In addition, Travere Therapeutics Inc saw 55.62% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TVTX starting from Meckler Jeffrey A, who sale 40,000 shares at the price of $14.06 back on Sep 30 ’24. After this action, Meckler Jeffrey A now owns 81,000 shares of Travere Therapeutics Inc, valued at $562,324 using the latest closing price.
JEFFREY MECKLER, the Director of Travere Therapeutics Inc, proposed sale 40,000 shares at $14.06 during a trade that took place back on Sep 30 ’24, which means that JEFFREY MECKLER is holding shares at $562,324 based on the most recent closing price.
Stock Fundamentals for TVTX
Current profitability levels for the company are sitting at:
- -2.13 for the present operating margin
- 0.82 for the gross margin
The net margin for Travere Therapeutics Inc stands at -0.82. The total capital return value is set at -0.88. Equity return is now at value -582.60, with -59.56 for asset returns.
Based on Travere Therapeutics Inc (TVTX), the company’s capital structure generated 0.96 points at debt to capital in total, while cash flow to debt ratio is standing at -0.75. The debt to equity ratio resting at 25.3. The interest coverage ratio of the stock is -67.71.
Currently, EBITDA for the company is -331.81 million with net debt to EBITDA at -1.09. When we switch over and look at the enterprise to sales, we see a ratio of 8.11. The receivables turnover for the company is 6.52for trailing twelve months and the total asset turnover is 0.32. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.04.
Conclusion
To sum up, Travere Therapeutics Inc (TVTX) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
